source
- Biotech firms must align operating models with their unique DNA, not rely on generic SMID templatesThe article points out that two biotech firms with similar head counts, pipelines and growth plans can operate very differently. One may build extensive internal development infrastructure, while t…
- UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 yearsThe results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2…BioSpace · 1mo ago↗ source
- AbbVie receives FDA approval for Parkinson’s drug Juvmo, a Cerevel acquisition asset